Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Calgon Carbon Corporation ( CCC - Analyst Report ) posted a loss of $4.5 million or 8 cents a share in third-quarter 2012 compared with a profit of $14.5 million or 25 cents a share a year ago. Excluding a restructuring charge of $8 million, the Pennsylvania-based pollution control company earned 6 cents a share in the quarter, which missed the Zacks Consensus Estimate of 12 cents.
Revenues
Revenues dipped 5.6% year over year to $135.5 million, and missed the Zacks Consensus Estimate of $143 million. Currency translation had a negative impact of $3.2 million on sales, stemming from a stronger dollar.
Revenues from the Activated Carbon and Service segment decreased 11.6% to about $115 million, due to lower demand for activated carbon in the municipal drinking water, environmental air, and wastewater markets.
Equipment revenues shot up 57.5% to $18.2 million on higher sales from ballast water treatment systems and ion exchange equipment. Consumer sales increased 13.3% to $2.3 million in the quarter, supported by higher demand for activated carbon cloth.
Margins and Expenses
Gross margin fell to 27.3% in the quarter from 33.8% a year ago, impacted by maintenance issues, delays associated with a capital project, and hurricane damage at the company’s Pearl River plant. Moreover, the company incurred a charge of $1.7 million related to the write-off of obsolete inventory.
Selling, administrative and research (SG&A) expenses rose 7.5% to $25.8 million. The company attributed the increase to a $1.7 million pension charge and $1.7 million related to an agreement with its former chief executive officer in July 2012.
Financials
Calgon Carbon ended the quarter with cash and cash equivalents of $18.7 million, compared with $13.6 million as of December 31, 2011. Total long-term debt stood at $0.3 million as of September 30, 2012, compared with $1.1 million as of December 31, 2011.
Outlook and Recommendation
Calgon Carbon remains confident in its ability to balance the need for future investment with its responsibility to provide short-term returns. Despite some challenges, the company expects to continue to capitalize on its growth opportunities. Healthy sales gains and strategic initiatives will be beneficial in the longer term. We, however, remain concerned about the economic challenges that it might face in the remainder of 2012. Moreover, escalating costs remain a headwind.
We currently have a long-term (more than 6 months) Neutral recommendation on Calgon Carbon. The company, which competes with MeadWestvaco Corporation ( MWV - Analyst Report ) , retains a Zacks #4 Rank, which translates into a short-term (1 to 3 months) Sell rating.
Read the full Analyst Report on MWV
Read the full Analyst Report on CCC